Daewoong, Indonesia's IPB to co-research on primate

It will support the establishment of a primate research center, commercialization of pharmaceuticals and medical devices

Daewoong, Indonesia's IPB to co-research on primate
Young-ae Lee 1
2024-06-27 16:24:05 0ae@hankyung.com
Bio & Pharma

South Korea's Daewoong Pharmaceutical Co. announced on Thursday that it signed a contract with Indonesia's Bogor Agricultural University (Institut Pertanian Bogor, IPB) for joint research on primates.

Daewoong Pharmaceutical will collaborate with IPB to establish a specialized primate research center, commercialize pharmaceuticals and medical devices through primate research, and foster veterinary talent.

The company explained that the specialized primate research center will help secure competitiveness in the preclinical stage by evaluating the toxicity and efficacy of new drug candidates.

The specific cooperation will be carried out through the Center for Primate Studies (Pusat Studi Satwa Primata, PSSP), a research institution under IPB.

Write to Young-ae Lee at 0ae@hankyung.com
#Daewoong Pharmaceutical #Bogor Agricultural University #IPB #primate research #new drug candidates

Daewoong Pharmaceutical digitizes DB of 800 mn chemical compounds

Daewoong Pharmaceutical digitizes DB of 800 mn chemical compounds

South Korea's Daewoong Pharmaceutical announced on Monday that it has established a drug development system Daewoong AI System (DAISY) which combines an 800 million-compound molecular model database with an artificial intelligence (AI) target substance discovery system.According to the company

Daewoong gets stem cell facility license in Indonesia

Daewoong gets stem cell facility license in Indonesia

South Korea's Daewoong Pharmaceutical announced on Tuesday that its subsidiary Daewoong Biologics Indonesia has obtained a stem cell Lab Operational License from the Indonesian Ministry of Health.The stem cell processing facility license permits facilities to research and produce stem cells. T

Daewoong exports $92.4 mn Depot injection tech to UAE

Daewoong exports $92.4 mn Depot injection tech to UAE

The headquarters of Daewoong Pharmaceutical South Korea's Daewoong Pharmaceutical announced on Monday that it exported its technology for clinical development and commercialization rights of its DWJ108U Depot injection (Leuprolide) product in the US to a UAE-based Zydus Worldwide DMCC.The contr

Daewoong Pharm set to export Envlo Tab to Russia, CIS

Daewoong Pharm set to export Envlo Tab to Russia, CIS

Daewoong Pharmaceutical, a leading South Korean pharmaceutical company will export its new diabetes drug Envlo Tab. (active ingredient:enavogliflozin), to Russia and the Commonwealth of Independent States (CIS). The company revealed on Friday that it has finalized a contract with JSC Pharmasyn

Daewoong Pharma, Merck team up for AI tech for new drug

Daewoong Pharma, Merck team up for AI tech for new drug

South Korea's Daewoong Pharmaceutical announced on Tuesday it signed with memorandum of understanding (MOU) with Merck Life Science to build an artificial intelligence (AI)-based new drug development platform and provide technology support the entire cycle of the development process. Merc
(* comment hide *}